Pharma BD Deal Intelligence
A durable but unspectacular oncology bolt-on: Lilly's $6.5B all-cash acquisition of ImClone gave it Erbitux and a pipeline that later yielded Cyramza, both still generating roughly $600M+ a year 15+ years on. Neither became a blockbuster, and a second pipeline asset, Portrazza, failed commercially—so the price was never fully validated by matching returns.
A durable but unspectacular oncology bolt-on — Erbitux and Cyramza both still sell 15+ years later, but neither became a blockbuster and the $6.5B price was never validated by a matching return.
Full analysis, sources & comparables →BMS, which co-markets Erbitux in the US, declined to top Lilly's $70/share bid (vs its own $62) and committed to ongoing collaboration with the new owner.
C&EN headlined 'Lilly to Pay Big for ImClone' — flagging the 51% premium over pre-bid price and 9% drop in Lilly shares on announcement as evidence of Wall…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Eli Lilly acquired ImClone Systems for $70 per share in cash, approximately $6.5 billion, after Bristol-Myers Squibb (ImClone's existing Erbitux co-marketing partner) declined to match the bid at its own $62-per-share offer. Lilly cited Erbitux and ImClone's broader oncology pipeline as the rationale for what it called one of the leading oncology franchises in the biopharmaceutical industry; the 51% premium drew some Wall Street skepticism, with Lilly shares falling roughly 9% on announcement. The deal closed November 24, 2008.
A durable but unspectacular oncology bolt-on — Erbitux and Cyramza both still sell 15+ years later, but neither became a blockbuster and the $6.5B price was never validated by a matching return.
Assessment window: 15yr post-close.
159K US cases/yr · $1.3B Erbitux 2007 global sales
Colorectal cancer is the second leading cause of cancer death in the US, with metastatic disease historically associated with poor 5-year survival (~17%). Treatment combines surgery, chemotherapy backbones (FOLFOX, FOLFIRI), and biologics including EGFR and VEGF inhibitors selected by molecular biomarkers (KRAS, BRAF, MSI status).
At the time of the 2008 Lilly-ImClone deal, the metastatic colorectal cancer biologic market was a duopoly: Genentech/Roche's Avastin (bevacizumab, anti-VEGF) and ImClone's Erbitux (cetuximab, anti-EGFR), with Amgen's Vectibix (panitumumab, anti-EGFR) entering as competition in 2006. Erbitux generated ~$1.3B in 2007 worldwide sales, commercialized in the US through ImClone's partnership with Bristol-Myers Squibb and ex-US through Merck KGaA. Lilly's strategic logic was Gemzar's looming 2010 patent expiration plus the desire to build oncology mass beyond Alimta. Analysts flagged the $70/share price (51% above pre-bid trading) as risky, with C&EN noting Lilly paid a steep premium that pressured shares (-9% on announcement). Erbitux's commercial trajectory was ultimately constrained by KRAS mutation testing requirements (post-2009) and by Avastin's broader label, peaking around $1.87B globally before facing biosimilar pressure.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / ImClone Systems Incorporated (this deal) | 2008 | $6.5B | 61 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |